pancreatic cancer

yellow light street light traffic pause slow delay

Pharma

Verastem mulls options on approved asset in pancreatic cancer

With solid but not stellar data on its approved oncology combo in pancreatic cancer, Verastem is mulling its R&D strategy.

Fraiser Kansteiner Jun 17, 2026 3:00pm

Revolution Medicines booth at ASCO 2026

Fierce Biotech

ASCO: RevMed confident in RAS leadership as rivals square up

May 31, 2026 8:00am

Astellas

Astellas lifts forecast as Vyloy surge counters trial miss

Feb 5, 2026 11:00am

Go sign green light

Merus' Bizengri wins FDA nod as 1st drug to target NRG1+ cancers

Dec 4, 2024 6:55pm

A histology stain of pancreatic ductal adenocarcinoma

PCI and ChiRhoClin partner to foil shortage of diagnostic drug

Nov 20, 2024 9:30am

Loew

Ipsen's Onivyde combo approved in first-line pancreatic cancer

Feb 13, 2024 4:31pm